Our Team

Prof. David Kaye., MBBS, PhD, FRACP, FACC, FESC


Prof Kaye is the founder and director of Cardiora. He currently holds the position of Senior Cardiologist in the Heart Failure-Transplant Unit at the Alfred Hospital, Melbourne and is Head of the Cardiology Division and an NHMRC Senior Principal Research Fellow at the Baker IDI Heart and Diabetes Institute. He is recognized internationally for his work on the pathophysiology of heart failure. His studies have identified a range of the fundamental mechanisms that contribute to the progressive nature of heart failure. He has published over 230 research articles.

Prof Kaye is the recipient of the Eric Sussman and RT Hall Prizes for research excellence from the College of Physicians and Cardiac Society. He was awarded the 2012 Eureka Prize for Medical Research Translation.

Dr. Chris Nave PhD, MBA


Chris Nave is a partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialization Fund.

Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.

Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry.

In October 2014, Chris was awarded the AusBiotech Johnson & Johnson Industry Leadership Award. Chris is currently a Director of OccuRx Pty Ltd, Osprey Medical Inc., PolyActiva Pty Ltd, Global Kinetics Corporation, Otifex Therapeutics Pty Ltd and Cardiora Pty Ltd. Chris was also Chairperson of Fibrotech Therapeutics at the time of its successful sale to Shire and a Director of Spinifex Pharmaceuticals at the time of its sale to Novartis. Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.

Guy Krippner BSc, PhD


Dr Guy Krippner is currently Head of the Medicinal Chemistry Facility at Baker IDI. He has 15 years of experience as a senior Medicinal Chemist within the Biotechnology industry; 7 years of which have been as Head of Medicinal Chemistry within three different organisations.

He has participated in and managed a diverse range of drug discovery and development projects at Biota Holdings, Prana Biotechnology Ltd Starpharma Ltd and Verva Pharmaceuticals Ltd and is currently responsible for the provision of medicinal chemistry services as a core facility to the research programs of Baker IDI. Dr Krippner is an inventor on 11 patent families.

Dr. Ingmar Wahlqvist MD, MBA


Ingmar is an investment manager with Brandon Capital Partners since 2009. Immediately prior to this, he worked as a Business Development Manager at Melbourne Ventures, commercialising technology from the University of Melbourne, a position which included a part-time secondment to GBS Venture Partners, a life-science venture capital group.

Before that, Ingmar spent several years working in the global commercial operations of Sanofi-Aventis in Paris, France, the majority in the cardiovascular franchise of global marketing, and in particular on Plavix, which during this time grew to be the second best-selling drug worldwide. Ingmar also worked with a number of early-stage companies in the health sector, and as a management consultant with The Boston Consulting Group, advising clients in a range of industries including financial services, airlines and manufacturing. He spent some years working in clinical medicine, largely in critical care (emergency, intensive care, anaesthetics) within major teaching hospitals.

Ingmar is a Director of Protego Medical Pty Ltd, an Alternative Director for PolyActiva P/L, and is a past Director of Med-e-Serv P/L. Ingmar earned his medical degree (MB BS) from Monash University, and his Masters of Business Administration (MBA) from Melbourne Business School, where he graduated with an Award of Distinction. He is a registered medical practitioner with the Medical Board of Australia, a Graduate of the Australian Institute of Company Directors and a member of AusBiotech.

Bob Soh MD

Chief Operating Officer

Bob completed his medical training in the University of Melbourne, and subsequently undertook his surgical residency in major teaching hospitals across Melbourne and Sydney. He also held teaching appointments in the University of Melbourne’s Department of Medicine until 2013.

Prior to joining Cardiora, Bob was appointed Senior Medical Officer in Nucleus Network, Australia’s largest clinical trials unit where he worked closely with various international biotech and pharmaceutical companies. To date, Bob has been an investigator in over 150 trials, and has been appointed honorary researcher with the Alfred’s Hospital. He has also been involved in various project management and business development roles, and has consulted for various biotech companies.

Bob is Cardiora’s Chief Operating Officer, and is currently a team member in Melbourne based VC firm, Brandon Capital Partners.

Scientific Advisors

Prof. Bill Abraham MD, FACP, FACC, FAHA, FESC, FRCP

Prof. Abraham is Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at the Ohio State University College of Medicine. Prof. Abraham earned his medical degree from Harvard Medical School, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advance Heart Failure/ Transplant Cardiology at the University of Colorado Health Sciences Centre.

Prof Abraham’s research interests include haemodynamic and neurohormonal mechanisms in heart failure, sleep disordered breathing in heart failure, and clinical drug and device trials in heart failure. Prof Abraham has participated as a site Principal Investigator in more than 100 multicenter clinical drug and device trials. Prof. Abraham has also participated in all regulatory phases of new drug and device development from pre-clinical evaluation to Pre-Market Approval and New Drug Application submission and approval.

Prof. Abraham has authored more than 700 original papers, abstracts, book chapters and review articles. His work has been published in high impact journals, including the New England Journal of Meicine, The Lancet, the Journal of the American Medical Association, Circulation, the European Heart Journal, and the Journal of the American College of Cardiology. Prof. Abraham has co-authored national heart failure practice guidelines and co-edited a leading textbook on heart failure entitled Heart Failure: A Practical Approach to Treatment. Prof Abraham serves on the editorial boards of several major journals. In 2014 and again in 2015, he was named to the Thomson Reuters Highly cited Researchers list and as one of The World’s Most Inflential Scientific Minds.

Prof. Mike Bristow, MD, PhD, FACC

Michael R. Bristow, MD, PhD is Professor of Medicine (Cardiology) at the University of Colorado Anschutz Medical Campus, and Director of the Section of Pharmacogenomics in the University of Colorado Cardiovascular Anschutz campuses.

Dr. Bristow received his MD and PhD in pharmacology in 1970 and 1971 from the University of Illinois Chicago MD/PhD Program, completed an NIH postdoctoral fellowship in pharmacology at the University of Illinois, and received his medical training at Stanford University. He remained at Stanford to complete a fellowship in cardiology, and joined the Cardiology faculty in 1979. He moved to the University of Utah in 1984, where he co-founded the first multi-hospital heart transplant program in the U.S. In 1991 he was recruited to the University of Colorado in Denver as Head of the Division of Cardiology, and served in that capacity until 2004.

Dr. Bristow has authored more than 400 peer-reviewed papers and chapters on heart failure, cardiac transplantation, pharmacogenomics and other cardiovascular topics. He has received many academic and industry honors, including the Therapeutics Frontiers Award by the American college of Clinical Pharmacy (1993), the Pharmaceutical Research and Manufacturers of America Clinical Trial Exceptional Service Award (2008), the Lifetime Achievement Award by the Heart Failure Society of America (2008), and Scientist of the Year by the Colorado Chapter of the ARCS Foundation (2008), University of Illinois Alumni Achievement Award, (2009) and the Distinguished Scientist Award (Translational Domain), by the American College of Cardiology (2014).

Dr. Bristow is also President and CEO of ARCA Biopharma; a Westminster, CO company he founded in 2003 to develop genetically targeted therapies for heart failure and other cardiovascular diseases. In 2007, he co-founded Miragen Therapeutics, Inc., a Boulder company dedicated to utilizing the biologic properties of microRNA in developing therapies for cardiovascular diseases. He was also the principal founder and former Chief Science and Medical Officer of Myogen, Inc., a Westminster, CO biopharmaceutical company that was acquired by Gilead Sciences in 2006. These companies, all founded on university-licensed intellectual property generated by Dr. Bristow and his collaborators, have been responsible for creating hundreds of jobs in Colorado, and have returned over $2 billion to investors.